Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition
Review

Targeting TDP-43 in sporadic amyotrophic lateral sclerosis

C. Estévez-Fraga R. Álvarez-Velasco T. Afroz M. R. Costa A. Jovičić Felix L. Yeh P. McColgan Andrea Malaspina Alexander McCampbell
Aug 2026 · Journal of Neurology · Vol 273 · 1 citation · 110 references
Medicine

TL;DR

Key biological mechanisms underlying TDP-43 pathology, emerging therapeutic strategies, and evolving approaches to clinical trial design and biomarker development are examined.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

TDP-43 overexpression induces cellular dysfunction and ALS-associated transcriptional changes

This stable, inducible TDP-43 overexpression model and its associated transcriptomic dataset provide a versatile platform for ALS and other TDP-43 proteinopathy research, enabling the investigation of molecular drivers of TDP-43 dysfunction, the identification of potential disease-relevant pharmacological targets, and...

Samantha A. DeSando, K. Mcclay, Amy N. Banks et al. · 0 citations
Review Jul 2026

Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000.

It is concluded that it is imperative that the field adopts more rigorous biomarker-led methodologies, and that although target-specific degraders offer a sophisticated technological leap, their success depends on addressing fundamental knowledge gaps in target engagement, age-dependent vector tropism, and trial design...

Michael A. S. Guth · 0 citations
Open access Aug 2026

Characterizing shared and distinctive molecular phenotypes across motor regions in ALS with and without TDP-43 pathology in a veteran cohort

These findings identify senescence-associated molecular states within vulnerable neuronal populations in ALS and support a model in which persistent stress adaptation may permit neuronal survival while contributing to progressive cellular dysfunction.

P. H. Doyle, Shiva Kazempour Dehkordi, Timothy C. Orr et al. · 0 citations
Review Open access Aug 2026

Prion-like Protein TDP-43: Mechanisms, Diagnosis, and Therapeutic Prospects

This review synthesizes how decoding the structural and RNA-metabolic complexities of TDP-43 is paving a promising pathway from bench to bedside, while critically discussing current translational limitations.

M. Shimamura, K. Satoh · 0 citations
Review Aug 2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

M. Benatar, SJ Barmada, Gregory A. Jicha et al. · 1 citation
Open access Aug 2026

Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model

Collectively, scFv B1 modulates upstream pathogenic processes associated with TDP-43 proteinopathy but is insufficient to reverse established neurodegeneration after symptom onset, underscoring the need for earlier and likely combinatorial intervention strategies in ALS.

Y. Al Ojaimi, A. Dupuis, M. Palla et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.